Bellicum

Rick Fair, President and CEO 

Oct. 11 | 4:30pm | Oxford Biomedica Ballroom 

Houston, TX 

(NASDAQ: BLCM) 

In-person Presentation 

Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR T cell products capable of overriding key immune inhibitory mechanisms. 

www.bellicum.com 

 



By using this website you agree to accept our Privacy Policy and Terms & Conditions